Micro-RNAs in thyroid neoplasms: Molecular, diagnostic and therapeutic implications

Journal of Clinical Pathology

Volumn 62, Issue 11, 2009, Pages 978-985

  Menon, M P ^a   Khan, A ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BINDING PROTEIN; CYCLIN D1; CYCLIN E; DOUBLE STRANDED RNA; MESSENGER RNA; MICRORNA; PROTEIN BCL 2; PROTEIN P53; RIBONUCLEASE III; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE; THYMOSIN BETA10; UVOMORULIN;

ANAPLASTIC CARCINOMA; ASPIRATION CYTOLOGY; BIOGENESIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; FOLLICULAR CARCINOMA; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; ONCOGENE C MYC; PAPILLARY CARCINOMA; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; RNA ANALYSIS; THYROID CARCINOMA; UNTRANSLATED REGION;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADENOMA; CARCINOMA; CELL DIFFERENTIATION; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROGNOSIS; RNA, NEOPLASM; THYROID NEOPLASMS;

EID: 73349112888     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2008.063909     Document Type: Review

References (93)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
2. Ambros V. MicroRNAs: tiny regulators with great potential. Cell 2001;107:823-6.
3. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003;113:673-6.
4. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.
5. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
6. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005;6:376-85.
7. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
8. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008;9:219-30.
9. Llave C, Xie Z, Kasschau KD, et al. Cleavage of Scarecrow-like mRNA targets directed by a class of Arabidopsis miRNA. Science 2002;297:2053-6.
10. Palatnik JF, Allen E, Wu X, et al. Control of leaf morphogenesis by microRNAs. Nature 2003;425:257-63.
11. Tang G, Reinhart BJ, Bartel DP, et al. A biochemical framework for RNA silencing in plants. Genes Dev 2003;17:49-63.
12. Carmell MA, Xuan Z, Zhang MQ, et al. The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev 2002;16:2733-42.
13. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993;75:855-62.
14. Olsen PH, Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol 1999;216:671-80.
15. Ambros V. Control of developmental timing in Caenorhabditis elegans. Curr Opin Genet Dev 2000;10:428-33.
16. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000;403:901-6.
17. Slack FJ, Basson M, Liu Z, et al. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. Mol Cell 2000;5:659-69.
18. Pasquinelli AE, Ruvkun G. Control of developmental timing by microRNAs and their targets. Annu Rev Cell Dev Biol 2002;18:495- 513.
19. Pillai RS, Bhattacharyya SN, Artus CG, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005;309:1573-6.
20. Cannell IG, Kong YW, Bushell M. How do microRNAs regulate gene expression? Biochem Soc Trans 2008;36(Pt 6):1224-31.
21. Kong YW, Cannell IG, de Moor CH, et al. The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target gene. Proc Natl Acad Sci USA 2008;105:8866-71.
22. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-31.
23. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res 2005;65:3509-12.
24. Yendamuri S, Calin GA. The role of microRNA in human leukemia: a review. Leukemia 2009;23:1257-63.
25. Fabbri M, Garzon R, Andreeff M, et al. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 2008;22:1095-105.
26. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004.
27. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-9.
28. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65:6029-33.
29. Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005;334:1351-8.
30. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. US and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000;89:202-17.
31. Baloch ZW, Livolsi V. Pathology of thyroid gland. In: Livolsi V, Asa SL, eds. Endocrine pathology. New York: Churchill Livingstone, 2002:61-88.
32. Gimm O. Thyroid cancer. Cancer Lett 2001;163:143-56.
33. Dal Maso L, Bosetti C, La Vecchia C, et al. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control 2009;20:75-86.
34. Rosai J, Carangui ML, DeLellis RA. Atlas of tumor pathology: tumors of the thyroid gland. Washington: Armed Forces Institute of Pathology, 1992.
35. Yamashita H, Noguchi Y, Noguchi S, et al. Significance of an insular component in follicular thyroid carcinoma with distant metastasis at initial presentation. Endocr Pathol 2005;16:41-8.
36. Jung TS, Kim TY, Kim KW, et al. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. Endocr J 2007;54:265-74.
37. Eszlinger M, Krohn K, Hauptmann S, et al. Perspectives for improved and more accurate classification of thyroid epithelial tumors. J Clin Endocrinol Metab 2008;93:3286-94.
38. Saxen VFK, Bjarnason O, Normann T, et al. Observer variation in histologic classification of thyroid cancer (A). Acta Pathol Microbiol Scand 1978;86A:483-6.
39. Franc B, de la Salmoniere P, Lange F, et al. Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol 2003;34:1092-100.
40. Visone R, Pallante P, Vecchione A, et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 2007;26:7590-5.
41. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306.
42. Finley DJ, Arora N, Zhu B, et al. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 2004;89:3214-23.
43. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 2001;98:15044-9.
44. Lubitz CC, Ugras SK, Kazam JJ, et al. Microarray analysis of thyroid nodule fineneedle aspirates accurately classifies benign and malignant lesions. J Mol Diagn 2006;8:490-8; quiz 528.
45. Scognamiglio T, Kao J, Fahey JT, et al. Papillary thyroid carcinoma vs follicular adenoma: molecular diagnosis by cumulative analysis of gene expression ratios [abstract]. Mod Pathol 2005;18:218A.
46. Hunt JL, Tometsko M, LiVolsi VA, et al. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 2003;27:1559-64.
47. Cerutti J, Trapasso F, Battaglia C, et al. Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines. Clin Cancer Res 1996;2:119-26.
48. Califano D, Monaco C, Santelli G, et al. Thymosin beta-10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro. Cancer Res 1998;58:823-8.
49. de Nigris F, Visconti R, Cerutti J, et al. Overexpression of the HIP gene coding for a heparin/heparan sulfate-binding protein in human thyroid carcinomas. Cancer Res 1998;58:4745-51.
50. Donghi R, Longoni A, Pilotti S, et al. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993;91:1753-60.
51. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol 2006;94:662-9.
52. Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 2004;15:319-27.
53. Wiseman SM, Griffith OL, Deen S, et al. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 2007;142:717-27; discussion 727-9.
54. Wiseman SM, Masoudi H, Niblock P, et al. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg 2006;191:581-7.
55. Elliott DD, Sherman SI, Busaidy NL, et al. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol 2008;39:15-20.
56. Wiseman SM, Masoudi H, Niblock P, et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 2007;14:719-29.
57. Martelli ML, Miano MG, Battaglia C, et al. The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive. Eur J Endocrinol 2000;143:515-21.
58. Cerutti JM, Delcelo R, Amadei MJ, et al. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 2004;113:1234-42.
59. Weber F, Shen L, Aldred MA, et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab 2005;90:2512-21.
60. Weber F, Teresi RE, Broelsch CE, et al. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006;91:3584-91.
61. Nikiforova MN, Tseng GC, Steward D, et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93:1600-8.
62. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7.
63. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005;115:1068-81.
64. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005;102:19075-80.
65. Pallante P, Visone R, Ferracin M, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006;13:497-508.
66. Russell JP, Powell DJ, Cunnane M, et al. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene 2000;19:5729-35.
67. Powell DJ Jr, Russell J, Nibu K, et al. The RET/PTC3 oncogene: metastatic solidtype papillary carcinomas in murine thyroids. Cancer Res 1998;58:5523-8.
68. Ledent C, Marcotte A, Dumont JE, et al. Differentiated carcinomas develop as a consequence of the thyroid specific expression of a thyroglobulin-human papillomavirus type 16 E7 transgene. Oncogene 1995;10:1789-97.
69. Altuvia Y, Landgraf P, Lithwick G, et al. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res 2005;33:2697-706.
70. Visone R, Russo L, Pallante P, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007;14:791-8.
71. Wang S, Wuu J, Savas L, et al. The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol 1998;29:1304-9.
72. Kim HJ, Kim YH, Lee DS, et al. In vivo imaging of functional targeting of miR-221 in papillary thyroid carcinoma. J Nucl Med 2008;49:1686-93.
73. Cillo C, Faiella A, Cantile M, et al. Homeobox genes and cancer. Exp Cell Res 1999;248:1-9.
74. Jazdzewski K, Murray EL, Franssila K, et al. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA 2008;105:7269-74.
75. Ledent C, Dumont J, Vassart G, et al. Thyroid adenocarcinomas secondary to tissuespecific expression of simian virus-40 large T-antigen in transgenic mice. Endocrinology 1991;129:1391-401.
76. Tallini G, Dal Cin P. HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors. Adv Anat Pathol 1999;6:237-46.
77. Fedele M, Battista S, Manfioletti G, et al. Role of the high mobility group A proteins in human lipomas. Carcinogenesis 2001;22:1583-91.
78. Chiappetta G, Bandiera A, Berlingieri MT, et al. The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 1995;10:1307-14.
79. Berlingieri MT, Pierantoni GM, Giancotti V, et al. Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 2002;21:2971-80.
80. Takakura S, Mitsutake N, Nakashima M, et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci 2008;99:1147-54.
81. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-33.
82. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-32.
83. Griffiths-Jones S, Grocock RJ, van Dongen S, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34:D140-4.
84. Frisk T, Foukakis T, Dwight T, et al. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer 2002;35:74-80.
85. Bruni P, Boccia A, Baldassarre G, et al. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000;19:3146-55.
86. Mitomo S, Maesawa C, Ogasawara S, et al. Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci 2008;99:280-6.
87. Hoang-Vu C, Boltze C, Gimm O, et al. Expression of telomerase genes in thyroid carcinoma. Int J Oncol 2002;21:265-72.
88. Ito Y, Yoshida H, Tomoda C, et al. Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT). Anticancer Res 2005;25:509-14.
89. Cameron J. Thyroid cancer. In: Cameron J, ed. Current surgical therapy. 8th edn. Philadelphia: Mosby, 2004:584-91.
90. Demay R. Thyroid. In: Demay R, ed. The art and science of cytopathology. Chicago: ASCP Press, 1996:724-40.
91. Mittendorf EA, Khiyami A, McHenry CR. When fine-needle aspiration biopsy cannot exclude papillary thyroid cancer: a therapeutic dilemma. Arch Surg 2006;141:961-6; discussion 966.
92. Chen H, Zeiger MA, Clark DP, et al. Papillary carcinoma of the thyroid: can operative management be based solely on fine-needle aspiration? J Am Coll Surg 1997;184:605-10.
93. Sclabas GM, Staerkel GA, Shapiro SE, et al. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg 2003;186:702-9; discussion 709-10.